MA55816A - Combinaisons thérapeutiques comprenant des immunoconjugués anti-cd123 - Google Patents
Combinaisons thérapeutiques comprenant des immunoconjugués anti-cd123Info
- Publication number
- MA55816A MA55816A MA055816A MA55816A MA55816A MA 55816 A MA55816 A MA 55816A MA 055816 A MA055816 A MA 055816A MA 55816 A MA55816 A MA 55816A MA 55816 A MA55816 A MA 55816A
- Authority
- MA
- Morocco
- Prior art keywords
- immunoconjugates
- combination therapies
- including anti
- therapies including
- combination
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962839974P | 2019-04-29 | 2019-04-29 | |
US201962860598P | 2019-06-12 | 2019-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA55816A true MA55816A (fr) | 2022-03-16 |
Family
ID=73029177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA055816A MA55816A (fr) | 2019-04-29 | 2020-04-29 | Combinaisons thérapeutiques comprenant des immunoconjugués anti-cd123 |
Country Status (11)
Country | Link |
---|---|
US (2) | US11701428B2 (fr) |
EP (1) | EP3962528A4 (fr) |
KR (1) | KR20220004669A (fr) |
CN (1) | CN113853217A (fr) |
AU (1) | AU2020265225A1 (fr) |
CA (1) | CA3137454A1 (fr) |
IL (1) | IL287446A (fr) |
MA (1) | MA55816A (fr) |
SG (1) | SG11202110702WA (fr) |
TW (1) | TW202106716A (fr) |
WO (1) | WO2020223351A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA55816A (fr) | 2019-04-29 | 2022-03-16 | Immunogen Inc | Combinaisons thérapeutiques comprenant des immunoconjugués anti-cd123 |
JP2024517318A (ja) * | 2021-05-11 | 2024-04-19 | アッヴィ・インコーポレイテッド | アザシチジンと組み合わせて骨髄異形成症候群の処置に使用されるベネトクラクス投与レジメン |
WO2024123765A1 (fr) * | 2022-12-08 | 2024-06-13 | Immunogen, Inc. | Combinaisons thérapeutiques comprenant des conjugués anticorps-médicament anti-cd123 et des anticorps anti-cd47 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8163279B2 (en) | 2007-04-13 | 2012-04-24 | Stemline Therapeutics, Inc. | IL3Rα antibody conjugates and uses thereof |
JP2011507933A (ja) * | 2007-12-26 | 2011-03-10 | バイオテスト・アクチエンゲゼルシヤフト | 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法 |
WO2012142411A1 (fr) * | 2011-04-15 | 2012-10-18 | Clavis Pharma Asa | Systèmes et procédés pour la détection d'une expression hent1 dans des troubles hématologiques |
TW201709932A (zh) | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Cd123抗體及其共軛物 |
EP3313845B1 (fr) | 2015-06-29 | 2020-08-12 | ImmunoGen, Inc. | Conjugués d'anticorps à cystéine modifiée |
CA2989321A1 (fr) * | 2015-06-29 | 2017-01-05 | Immunogen, Inc. | Anticorps anti-cd 123 et conjugues et derives correspondants |
SG11201802964QA (en) * | 2015-10-15 | 2018-05-30 | Celgene Corp | Combination therapy for treating malignancies |
US10959993B2 (en) * | 2015-11-03 | 2021-03-30 | Genentech, Inc. | Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer |
JP2019501139A (ja) | 2015-11-25 | 2019-01-17 | イミュノジェン・インコーポレーテッド | 医薬製剤及びその使用 |
WO2017160954A1 (fr) * | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinaisons de conjugués anticorps-médicament à base de pbd et d'inhibiteurs de bcl-2 |
EP3318276A1 (fr) * | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques |
CA3044391A1 (fr) | 2016-11-23 | 2018-05-31 | Immunogen, Inc. | Sulfonation selective de derives de benzodiazepine |
GB2567613A (en) * | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
WO2018236904A1 (fr) * | 2017-06-19 | 2018-12-27 | Surface Oncology, Inc. | Combinaison d'anticorps anti-cd47 et d'agents induisant la mort cellulaire, et leurs utilisations |
BR112020000492A2 (pt) * | 2017-07-09 | 2020-07-14 | Biosight Ltd. | terapia de câncer de combinação |
WO2019020606A1 (fr) * | 2017-07-26 | 2019-01-31 | F. Hoffmann-La Roche Ag | Polythérapie avec un inhibiteur bet, un inhibiteur bcl-2 et un anticorps anti-cd20 |
MA50195A (fr) | 2017-09-22 | 2020-07-29 | Immunogen Inc | Séparation d'anticorps à chaîne triple légère à l'aide d'une chromatographie à échange de cations |
EP4374850A2 (fr) | 2017-09-22 | 2024-05-29 | ImmunoGen, Inc. | Procédés de prévention de l'oxydation de méthionine dans des immunoconjugués |
US20200157228A1 (en) | 2018-10-30 | 2020-05-21 | Immunogen, Inc. | Methods of treatment using anti-cd123 immunoconjugates |
MA55816A (fr) | 2019-04-29 | 2022-03-16 | Immunogen Inc | Combinaisons thérapeutiques comprenant des immunoconjugués anti-cd123 |
-
2020
- 2020-04-29 MA MA055816A patent/MA55816A/fr unknown
- 2020-04-29 EP EP20798446.9A patent/EP3962528A4/fr active Pending
- 2020-04-29 AU AU2020265225A patent/AU2020265225A1/en active Pending
- 2020-04-29 KR KR1020217036821A patent/KR20220004669A/ko unknown
- 2020-04-29 WO PCT/US2020/030478 patent/WO2020223351A1/fr unknown
- 2020-04-29 CA CA3137454A patent/CA3137454A1/fr active Pending
- 2020-04-29 TW TW109114329A patent/TW202106716A/zh unknown
- 2020-04-29 CN CN202080037081.6A patent/CN113853217A/zh active Pending
- 2020-04-29 SG SG11202110702WA patent/SG11202110702WA/en unknown
- 2020-04-29 US US16/862,358 patent/US11701428B2/en active Active
-
2021
- 2021-10-20 IL IL287446A patent/IL287446A/en unknown
-
2023
- 2023-06-02 US US18/328,288 patent/US20240033371A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020265225A1 (en) | 2021-10-28 |
US20210023237A1 (en) | 2021-01-28 |
EP3962528A4 (fr) | 2023-01-11 |
US20240033371A1 (en) | 2024-02-01 |
IL287446A (en) | 2021-12-01 |
SG11202110702WA (en) | 2021-11-29 |
JP2022533009A (ja) | 2022-07-21 |
CN113853217A (zh) | 2021-12-28 |
TW202106716A (zh) | 2021-02-16 |
WO2020223351A1 (fr) | 2020-11-05 |
KR20220004669A (ko) | 2022-01-11 |
EP3962528A1 (fr) | 2022-03-09 |
CA3137454A1 (fr) | 2020-11-05 |
US11701428B2 (en) | 2023-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202102016B (en) | Combination therapies | |
MA42844A (fr) | Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1 | |
MA52884A (fr) | Anticorps anti-il-11 | |
IL291659A (en) | Combined treatments | |
MA52152A (fr) | Anticorps | |
ZA202102015B (en) | Combination therapies | |
MA52366A (fr) | Anticorps anti-tl1a optimisés | |
CL2019003599S1 (es) | Extintor. | |
MA55816A (fr) | Combinaisons thérapeutiques comprenant des immunoconjugués anti-cd123 | |
DK3767254T3 (da) | Kombinationsvejeindretning | |
MA49977A (fr) | Combinaisons pharmaceutiques comprenant un anticorps anti-ly75 | |
MA49822A (fr) | Combinaison pharmaceutique comprenant du ponesimod | |
DK3706710T3 (da) | Formuleringer med forlænget frigivelse til intraartikulære anvendelser | |
GB201811477D0 (en) | Runtime analysis | |
DK3598085T3 (da) | Kombinationsvejeindretning | |
DK3792604T3 (da) | Kombinationsvejeindretning | |
IL287667A (en) | Combined treatments | |
MA42978A (fr) | Formulations ec comprenant des insecticides organophosphatés | |
GB201916906D0 (en) | Combination therapies | |
MA42977A (fr) | Formulations ec comprenant des insecticides organophosphatés | |
IT201900021636A1 (it) | Unità dosatrice | |
IT201900022578A1 (it) | Dispositivo per parrucchieri. | |
JP1737645S (ja) | 引手 | |
UA41389S (uk) | Дискова борона навісна | |
UA41390S (uk) | Дискова борона навісна |